- 舍曲林个体化治疗原发性早泄的疗效分析
- 作者:严肃|发布时间:2011-06-26|浏览量:6526次
严肃 李汉忠 张新宇 李宏军
【摘要】目的比较不同剂量舍曲林治疗原发性早泄的临床疗效。方法选择86例符合原发性早泄诊断的患者,治疗前评估国际勃起功能评分表、中国早泄患者性功能评价表。第一阶段治疗4周,每日服用盐酸舍曲林50 mg并配合行为疗法。4周后,根据疗效和不良反应将患者分为3组进入第_二阶段治疗4周:有效且无或有轻微不良反应者继续原治疗;无效但无明显不良反应者,舍曲林剂量调整为每日100 mg;有效但有明显不良反应者舍曲林剂量调整为每日25 mg;无效且有明显不良反应、不能耐受者退出观察。结果86例第一阶段4周治疗后,有效63例(73.3%),无效23例(26.7%)。其中,无明显不良反应53例(61.6%),有不良反应33例(38.4%)。第二阶段治疗中,有效组中35例无明显不良反应和12例有轻微不良反应者继续原治疗,16例有明显不良反应且不能耐受者舍曲林剂量调整为每日25 mg。无效组中,18例无明显不良反应者将舍曲林剂量调整为每日100 mg,5例退出观察。8周治疗后,50 mg组47例均有效,无明显不良反应;25 mg组中有效10例,无效6例,2例有轻微不良反应且可耐受;100 mg组中有效8例(44.4%)。13例(72.2%)有不良反应但可以耐受,z例因明显不良反应退出治疗,1例无效且无明显不良反应。8周总有效率80.2%(65/81),总不良反应发生率21.0%(17/81)。结论舍曲林治疗原发性早泄安全有效,个体化治疗方案有效率无明显变化。不良反应发生率显著降低,患者对治疗的依从性增加。北京协和医院泌尿外科严肃
【关键词】勃起功能障碍; 早泄; 药物疗法
Analyse OlI individualized treatment of idiopathic premature ejaculation with sertraline yAN Su.LI
Han?zhong。ZHANG Xin?yu,LJ Hong-jun.Department o/。Urology,Peking Union Medical Col?
lege Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing
100730,China
Corresponding author:LI Han-zhong,Email:lihanzhong@medimail.corn.c?l
[Abstract]Objective To compare the therapeutic effects with different dosages of sertraline on
patients suffering from idiopathic premature ejaculation. Methods IIEF-5 and CIPE questionnaires
were completed before the treatment,and 86 patients who met the diagnostic standard of idiopathic
premature ejaculation were finally recruited.Subiects were administered sertraline 50 mg/d combined
with behavior therapy at stage I for 4 weeks.Then,according to the therapeutic effects and the ad?
verse events,all of the patients were divided into 3 groups for stage 11(another 4 weeks)as follows:
①subjects with good effectiveness but with no or slight adverse events,would continue the treatment;
②subjects with no therapeutic effects and with no obvious adverse events were allowed to increase the
dosage of sertraline to 1 00 mg/d;③patients with effectiveness and obvious adverse events were allowed
to reduce the dosage of sertraline to 25 mg/d.Those who had obvious adverse events and no ef?
fectiveness quit the study. Results During stage I,63 of 86 patients were effective(73.3%),and
23 patients had no improvement(26.7%).Thirty?three patients had adverse events(38.4%),and
the remaining 53 patients had no obvious adverse events(61.6%).During stage II。of the patients
that responded to treatment?35 patients who had no adverse events and 12 who had slight adverse e?
vents continued the treatment.Furthermore,l 6 with intolerable adverse events were allowed to reduce
the dosage to 25 mg/d.Meanwhile,of those without improvement,18 SUbjects without obvious
DOI:10.3760/cma.j.issn.1000?6702.2011.03.011
作者单位:100730中国医学科学院北京协和医学院北京协和医院泌尿外科
通信作者:李汉忠.Email:lihanzhong@medimail.tom.ca
万方数据